University of Cambridge > > MRC Mitochondrial Biology Unit Seminars > Targeting liver mitochondria to treat MASLD/MASH and cardiometabolic disease

Targeting liver mitochondria to treat MASLD/MASH and cardiometabolic disease

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Lisa Arnold.

Insulin resistance is a critical factor in the pathogenesis of type 2 diabetes. In addition insulin resistance plays a key role in the pathogenesis of MASLD /MASH, heart disease, obesity-associated cancers and Alzheimer’s disease. In this lecture I will review recent studies that have demonstrated the safety and efficacy of liver-targeted mitochondrial uncoupling agents to treat these diseases in both animal models and humans with MASLD /MASH and cardiometabolic disease. I will also review some novel 13C NMR and LC-MS/MS methods (PINTA and Q-Flux) that we have recently developed to assess rates of hepatic mitochondrial oxidation and anaplerotic fluxes in vivo.

This talk is part of the MRC Mitochondrial Biology Unit Seminars series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity